Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients

mBio

Volumn 5, Issue 2, 2014, Pages

  Saijo, Tomomi ^a   Chen, Jianghan ^b   Chen, Sharon C A ^c,d   Rosen, Lindsey B ^a   Yi, Jin ^b   Sorrell, Tania C ^c,d   Bennett, John E ^a   Holland, Steven M ^a   Browne, Sarah K ^a   Kwon Chung, Kyung J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c WESTMEAD HOSPITAL   (Australia)

^d University of Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY;

ADULT; ANTIBODY DETECTION; ARTICLE; AUSTRALIA; BACTERIAL STRAIN; CHILD; CHINA; CLINICAL ARTICLE; CONTROLLED STUDY; CRYPTOCOCCAL MENINGOENCEPHALITIS; CRYPTOCOCCUS GATTII; DISEASE PREDISPOSITION; FEMALE; HUMAN; IMMUNOCOMPETENCE; MALE; MENINGOENCEPHALITIS; MIDDLE AGED; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCREENING; YOUNG ADULT;

ADULT; AUSTRALIA; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; CHINA; CRYPTOCOCCUS GATTII; DISEASE SUSCEPTIBILITY; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 84899710728     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00912-14     Document Type: Article

References (51)

1. Kwon-Chung KJ, Bennett JE. 1992. Medical mycology, p 44-78. Lea & Febiger, Pennsylvania, PA.
2. Sorrell TC. 2001. Cryptococcus neoformans variety gattii. Med. Mycol. 39:155-168. http://dx.doi.org/10.1080/714031012.
3. Hajjeh RA, Conn LA, Stephens DS, Baughman W, Hamill R, Graviss E, Pappas PG, Thomas C, Reingold A, Rothrock G, Hutwagner LC, Schuchat A, Brandt ME, Pinner RW. 1999. Cryptococcosis: populationbased multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J. Infect. Dis. 179:449-454. http://dx.doi.org/10.1086/314606.
4. Chen S, Sorrell T, Nimmo G, Speed B, Currie B, Ellis D, Marriott D, Pfeiffer T, Parr D, Byth K. 2000. Epidemiology and host-and varietydependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin. Infect. Dis. 31:499-508. http://dx.doi.org/10.1086/313992.
5. Choi YH, Ngamskulrungroj P, Varma A, Sionov E, Hwang SM, Carriconde F, Meyer W, Litvintseva AP, Lee WG, Shin JH, Kim EC, Lee KW, Choi TY, Lee YS, Kwon-Chung KJ. 2010. Prevalence of the VNIc genotype of Cryptococcus neoformans in non-HIV-associated cryptococcosis in the Republic of Korea. FEMS Yeast Res. 10:769-778. http://dx.doi.org/ 10.1111/j.1567-1364.2010.00648.x.
6. Mihara T, Izumikawa K, Kakeya H, Ngamskulrungroj P, Umeyama T, Takazono T, Tashiro M, Nakamura S, Imamura Y, Miyazaki T, Ohno H, Yamamoto Y, Yanagihara K, Miyzaki Y, Kohno S. 2013. Multilocus sequence typing of Cryptococcus neoformans in non-HIV associated cryptococcosis in Nagasaki, Japan. Med. Mycol. 51:252-260. http://dx.doi.org/ 10.3109/13693786.2012.708883.
7. Rosen LB, Freeman AF, Yang LM, Jutivorakool K, Olivier KN, Angkasekwinai N, Suputtamongkol Y, Bennett JE, Pyrgos V, Williamson PR, Ding L, Holland SM, Browne SK. 2013. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J. Immunol. 190:3959-3966. http://dx.doi.org/10.4049/jimmunol.1202526.
8. Kitamura T, Tanaka N, Watanabe J, Uchida, Kanegasaki S, Yamada Y, Nakata K. 1999. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 190:875-880. http://dx.doi.org/ 10.1084/jem.190.6.875.
9. Rosen SH, Castleman B, Liebow AA. 1958. Pulmonary alveolar proteinosis. N. Engl. J. Med. 258:-1123-1142. http://dx.doi.org/10.1056/ NEJM195806052582301.
10. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50:291-322. http://dx.doi.org/10.1086/649858.
11. Trapnell BC, Whitsett JA, Nakata K. 2003. Pulmonary alveolar proteinosis. N. Engl. J. Med. 349:2527-2539. http://dx.doi.org/10.1056/ NEJMra023226.
12. Tanaka N, Watanabe J, Kitamura T, Yamada Y, Kanegasaki S, Nakata K. 1999. Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor. FEBS Lett. 442:246-250. http://dx.doi.org/10.1016/S0014-5793(98)01668-8.
13. Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA, Trapnell BC. 2001. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 15:557-567. http:// dx.doi.org/10.1016/S1074-7613(01)00218-7.
14. Uchida K, Beck DC, Yamamoto T, Berclaz PY, Abe S, Staudt MK, Carey BC, Filippi MD, Wert SE, Denson LA, Puchalski JT, Hauck DM, Trapnell BC. 2007. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N. Engl. J. Med. 356:567-579. http:// dx.doi.org/10.1056/NEJMoa062505.
15. Subramanian Vignesh K, Landero Figueroa JA, Porollo A, Caruso JA, Deepe GS, Jr. 2013. Granulocyte macrophage-colony stimulating factor induced Zn sequestration enhances macrophage superoxide and limits intracellular pathogen survival. Immunity 39:697-710. http://dx.doi.org/ 10.1016/j.immuni.2013.09.006.
16. Shi Y, Liu CH, Roberts AI, Das J, Xu G, Ren G, Zhang Y, Zhang L, Yuan ZR, Tan HS, Das G, Devadas S. 2006. Granulocyte-macrophage colonystimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res. 16:126-133. http://dx.doi.org/10.1038/sj.cr.7310017.
17. Wada H, Noguchi Y, Marino MW, Dunn AR, Old LJ. 1997. T cell functions in granulocyte/macrophage colony-stimulating factor deficient mice. Proc. Natl. Acad. Sci. U. S. A. 94:12557-12561. http://dx.doi.org/ 10.1073/pnas.94.23.12557.
18. Sorrell TC, Chen SC-A, Phillips P, Marr KA. 2010. Clinical perspectives on Cryptococcus neoformans and Cryptococcus gattii: implications for diagnosis and management, p 595-606. In Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A (ed), Cryptococcus: from human pathogen to model yeast. ASM Press, Washington, DC.
19. Meyer W, Trilles L. 2010. Genotyping of the Cryptococcus neoformans/ C. gattii species complex. Aust. Biochemist 41:12-15. http://www.asbmb.org. au/magazine/2010-April_Issue41-1/Showcase%203%20-%20Meyer.pdf.
20. Chen SC, Slavin MA, Heath CH, Playford EG, Byth K, Marriott D, Kidd SE, Bak N, Currie B, Hajkowicz K, Korman TM, McBride WJ, Meyer W, Murray R, Sorrell TC; Australia and New Zealand Mycoses Interest Group (ANZMIG)-Cryptococcus Study. 2012. Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin. Infect. Dis. 55:789-798. http://dx.doi.org/10.1093/cid/cis529.
21. Galanis E, Macdougall L, Kidd S, Morshed M, British Columbia Cryptococcus gattii Working Group. 2010. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerg. Infect. Dis. 16: 251-257. http://dx.doi.org/10.3201/eid1602.090900.
22. Cheng PY, Sham A, Kronstad JW. 2009. Cryptococcus gattii isolates from the British Columbia cryptococcosis outbreak induce less protective inflammation in a murine model of infection than Cryptococcus neoformans. Infect. Immun. 77:4284-4294. http://dx.doi.org/10.1128/IAI.00628-09.
23. Schoffelen T, Illnait-Zaragozi MT, Joosten LA, Netea MG, Boekhout T, Meis JF, Sprong T. 2013. Cryptococcus gattii induces a cytokine pattern that is distinct from other cryptococcal species. PLoS One 8:e55579. http:// dx.doi.org/10.1371/journal.pone.0055579.
24. Leongson K, Cousineau-Côté V, Goupil M, Aumont F, Sénéchal S, Gaboury L, Jolicoeur P, Kronstad JW, de Repentigny L. 2013. Altered immune response differentially enhances susceptibility to Cryptococcus neoformans and Cryptococcus gattii infection in mice expressing the HIV-1 transgene. Infect. Immun. 81:1100-1113. http://dx.doi.org/10.1128/ IAI.01339-12.
25. Ngamskulrungroj P, Chang Y, Sionov E, Kwon-Chung KJ. 2012. The primary target organ of Cryptococcus gattii is different from that of Cryptococcus neoformans in a murine model. mBio 3:e00103-12. http:// dx.doi.org/10.1128/mBio.00103-12.
26. Ma H, Hagen F, Stekel DJ, Johnston SA, Sionov E, Falk R, Polacheck I, Boekhout T, May RC. 2009. The fatal fungal outbreak on Vancouver Island is characterized by enhanced intracellular parasitism driven by mitochondrial regulation. Proc. Natl. Acad. Sci. U. S. A. 106:12980-12985. http://dx.doi.org/10.1073/pnas.0902963106.
27. Voelz K, Lammas DA, May RC. 2009. Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans. Infect. Immun. 77:3450-3457. http://dx.doi.org/10.1128/ IAI.00297-09.
28. Olszewski MA, Zhang Y, Huffnagle GB. 2010. Mechanisms of cryptococcal virulence and persistence. Future Microbiol. 5:1269-1288. http:// dx.doi.org/10.2217/fmb.10.93.
29. van de Laar L, Coffer PJ, Woltman AM. 2012. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood 119:3383-3393. http:// dx.doi.org/10.1182/blood-2011-11-370130.
30. Lacey DC, Achuthan A, Fleetwood AJ, Dinh H, Roiniotis J, Scholz GM, Chang MW, Beckman SK, Cook AD, Hamilton JA. 2012. Defining GM-CSF-and macrophage-CSF-dependent macrophage responses by in vitro models. J. Immunol. 188:5752-5765. http://dx.doi.org/10.4049/ jimmunol.1103426.
31. Deepe GS, Jr, Gibbons R, Woodward E. 1999. Neutralization of endogenous granulocyte-macrophage colony-stimulating factor subverts the protective immune response to Histoplasma capsulatum. J. Immunol. 163:-4985-4993.
32. Huston SM, Li SS, Stack D, Timm-McCann M, Jones GJ, Islam A, Berenger BM, Xiang RF, Colarusso P, Mody CH. 2013. Cryptococcus gattii is killed by dendritic cells, but evades adaptive immunity by failing to induce dendritic cell maturation. J. Immunol. 191:249-261. http:// dx.doi.org/10.4049/jimmunol.1202707.
33. Osterholzer JJ, Chen GH, Olszewski MA, Curtis JL, Huffnagle GB, Toews GB. 2009. Accumulation of CD11b+ lung dendritic cells in response to fungal infection results from the CCR2-mediated recruitment and differentiation of Ly-6Chigh monocytes. J. Immunol. 183:8044-8053. http://dx.doi.org/10.4049/jimmunol.0902823.
34. Punatar AD, Kusne S, Blair JE, Seville MT, Vikram HR. 2012. Opportunistic infections in patients with pulmonary alveolar proteinosis. J. Infect. 65:173-179. http://dx.doi.org/10.1016/j.jinf.2012.03.020.
35. Seaton RA, Hamilton AJ, Hay RJ, Warrell DA. 1996. Exposure to Cryptococcus neoformans var. gattii-a seroepidemiological study. Trans. R. Soc. Trop. Med. Hyg. 90:508-512. http://dx.doi.org/10.1016/S0035-9203(96)90297-7.
36. Abadi J, Pirofski La. 1999. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection. J. Infect. Dis. 180:915-919. http://dx.doi.org/10.1086/314953.
37. Goldman DL, Khine H, Abadi J, Lindenberg DJ, Pirofski La, Niang R, Casadevall A. 2001. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107:E66. http://dx.doi.org/10.1542/ peds.107.5.e66.
38. Garcia-Hermoso D, Janbon G, Dromer F. 1999. Epidemiological evidence for dormant Cryptococcus neoformans infection. J. Clin. Microbiol. 37:3204-3209.
39. Hagen F, Colom MF, Swinne D, Tintelnot K, Iatta R, Montagna MT, Torres-Rodriguez JM, Cogliati M, Velegraki A, Burggraaf A, Kamermans A, Sweere JM, Meis JF, Klaassen CH, Boekhout T. 2012. Autochthonous and dormant Cryptococcus gattii infections in Europe. Emerg. Infect. Dis. 18:1618-1624. http://dx.doi.org/10.3201/eid1810.120068.
40. Svenson M, Hansen MB, Ross C, Diamant M, Rieneck K, Nielsen H, Bendtzen K. 1998. Antibody to granulocyte-macrophage colonystimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 91:2054-2061.
41. Uchida K, Nakata K, Suzuki T, Luisetti M, Watanabe M, Koch DE, Stevens CA, Beck DC, Denson LA, Carey BC, Keicho N, Krischer JP, Yamada Y, Trapnell BC. 2009. Granulocyte/macrophage-colonystimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 113:2547-2556. http://dx.doi.org/10.1182/blood-2009-05-155689.
42. Revoltella RP, Laricchia Robbio L, Liberati AM, Reato G, Foa R, Funaro A, Vinante F, Pizzolo G. 2000. Antibodies binding granulocytemacrophage colony stimulating factor produced by cord blood-derived B cell lines immortalized by Epstein-Barr virus in vitro. Cell. Immunol. 204: 114-127. http://dx.doi.org/10.1006/cimm.2000.1704.
43. Kitamura T, Uchida K, Tanaka N, Tsuchiya T, Watanabe J, Yamada Y, Hanaoka K, Seymour JF, Schoch OD, Doyle I, Inoue Y, Sakatani M, Kudoh S, Azuma A, Nukiwa T, Tomita T, Katagiri M, Fujita A, Kurashima A, Kanegasaki S, Nakata K. 2000. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am. J. Respir. Crit. Care Med. 162:658-662. http://dx.doi.org/10.1164/ajrccm.162.2.9910032.
44. Watanabe M, Uchida K, Nakagaki K, Trapnell BC, Nakata K. 2010. High avidity cytokine autoantibodies in health and disease: pathogenesis and mechanisms. Cytokine Growth Factor Rev. 21:263-273. http:// dx.doi.org/10.1016/j.cytogfr.2010.03.003.
45. Mausberg AK, Jander S, Reichmann G. 2009. Intracerebral granulocytemacrophage colony-stimulating factor induces functionally competent dendritic cells in the mouse brain. Glia 57:1341-1350. http://dx.doi.org/ 10.1002/glia.20853.
46. Hunter CA, Roberts CW, Alexander J. 1992. Kinetics of cytokine mRNA production in the brains of mice with progressive toxoplasmic encephalitis. Eur. J. Immunol. 22:2317-2322. http://dx.doi.org/10.1002/ eji.1830220921.
47. Centers for Disease Control and Prevention. 2010. Emergence of Cryptococcus gattii-Pacific Northwest, 2004-2010. MMWR Morb. Mortal. Wkly. Rep. 59:865-868.
48. Meyer W, Castañeda A, Jackson S, Huynh M, Castañeda E; IberoAmerican Cryptococcal Study. 2003. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg. Infect. Dis. 9:189-195. http://dx.doi.org/10.3201/eid0902.020246.
49. Ding L, Mo A, Jutivorakool K, Pancholi M, Holland SM, Browne SK. 2012. Determination of human anticytokine autoantibody profiles using a particle-based approach. J. Clin. Immunol. 32:238-245. http:// dx.doi.org/10.1007/s10875-011-9621-8.
50. Holland SM, Dorman SE, Kwon A, Pitha-Rowe IF, Frucht DM, Gerstberger SM, Noel GJ, Vesterhus P, Brown MR, Fleisher TA. 1998. Abnormal regulation of interferon-gamma, interleukin-12, and tumor necrosis factor-alpha in human interferon-gamma receptor 1 deficiency. J. Infect. Dis. 178:1095-1104. http://dx.doi.org/10.1086/515670.
51. Patel SY, Ding L, Brown MR, Lantz L, Gay T, Cohen S, Martyak LA, Kubak B, Holland SM. 2005. Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J. Immunol. 175: 4769-4776.